Moderna partners with UK govt on mRNA therapies and vaccines facility

US mRNA biotech Moderna (Nasdaq: MRNA), flush with cash due to the success of its COVID-19 vaccine Spikevax, today announced finalizing a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in the UK. This milestone follows the agreement in principle between Moderna and the UK government, announced in June 2022.

As a result, National Health Service (NHS) patients will have access to a UK-made supply of Covid jabs as well as cutting-edge vaccines developed for other respiratory diseases, such as flu and respiratory syncytial virus (RSV), said the UK Department of Health and Social Care. The deal is also a major boost for UK health research and will see the UK Health Security Agency (UKHSA) working with Moderna to ensure early vaccine development, supporting the G7 mission to get from variant to vaccine in 100 days.

The details of the strategic partnership between the government and Moderna are commercially sensitive, and are therefore not disclosed.